Eli Lilly and Company is committed to meeting the needs of people living with diabetes and obesity with treatment options that change the way healthcare providers can treat these diseases. Today, we are publishing an open letter to ensure that people living with diabetes and obesity, their families, and their healthcare providers are informed about potentially serious risks posed by the proliferation of counterfeit, fake, compounded, and other unsafe or untested versions of our FDA-approved tirzepatide medications (Mounjaro and Zepbound) and about appropriate use of our authentic medicines.
Lilly Warns Patients About Counterfeit and Compounded Medicines Releases Open Letter and Takes Further Legal Action Against Counterfeit, Fake, Unsafe, and Untested Products
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.